i-SENS
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
i-SENS makes medical sensors and measuring instruments that let people check their own blood-glucose levels at home, as well as diagnostic equipment used by hospitals at the point of care, meaning tests done on-site rather than sent to a lab.
Its products are used by both individual patients managing diabetes and by healthcare professionals in clinical settings. The company's two core business lines are its consumer blood-glucose monitoring segment and its point-of-care testing segment, listed on KOSDAQ, South Korea's tech-focused smaller-company board.
Summary is AI-generated and may contain errors · figures from DART filings
i-SENS in five facts
What does i-SENS do?
i-SENS makes medical sensors and measuring instruments that let people check their own blood-glucose levels at home, as well as diagnostic equipment used by hospitals at the point of care, meaning tests done on-site rather than sent to a lab.
Where is i-SENS listed and in which sector?
i-SENS (Korean name: 아이센스) trades under KRX code 099190 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is i-SENS?
Its market capitalisation was US$365.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were i-SENS's latest annual revenue and operating profit?
For fiscal year 2025, i-SENS reported revenue of US$238.1M, operating profit of US$6M and a net loss of US$12.1M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 8.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 1
- Report on securities held by executives/major shareholdersSep 21
- Conversion price adjustmentAug 31
- Early redemption of convertible bonds (incl. overseas CBs)
i-SENS, Inc. acquired US$1.01M face value of its 1st-round convertible bonds before maturity on July 30, 2026, following the bondholder's exercise of a put option, leaving US$12.5M of face value outstanding; the bonds will be retired via deregistration with the Korea Securities Depository.
Capital raise · Jul 30 - Operating results (consolidated) (preliminary) (fair disclosure)
i-SENS filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$60.4M (+15.2% year on year), operating profit of US$4.29M (+274.1% year on year) and net income of US$2.37M (+341.9% year on year).
Earnings · Jul 27 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Apr 30
- Operating results (consolidated) (preliminary) (fair disclosure)
i-SENS filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$50.6M (−2.3% year on year), operating profit of US$552K (−74.9% year on year) and net income of US$967K (−35.6% year on year).
Earnings · Apr 27 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
i-SENS reported consolidated results for FY2025: revenue of US$216M (+8.4% year on year), operating profit of US$5.69M (+212.4% year on year) and a net loss of US$5.68M.
Earnings · Feb 10 - Cash/in-kind dividend decision
i-SENS declared a cash dividend of US$0.07 per share.
Dividend · Feb 10